{"id":3536,"date":"2022-08-29T09:08:34","date_gmt":"2022-08-29T07:08:34","guid":{"rendered":"https:\/\/wp.idlbiotech.com\/?page_id=3536"},"modified":"2023-08-10T14:11:42","modified_gmt":"2023-08-10T12:11:42","slug":"tk-210-elisa","status":"publish","type":"page","link":"https:\/\/idldiagnostics.com\/se\/products\/oncology\/tk-210-elisa\/","title":{"rendered":"TK 210 ELISA"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.18.0″ _module_preset=”88f366a5-bf49-48d9-a338-ab22706b73e7″ custom_margin=”||||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” custom_padding=”0px||0px|||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”||||false|false” custom_padding_tablet=”10px||||false|false” custom_padding_phone=”0px||||false|false” custom_padding_last_edited=”on|phone” global_colors_info=”{}”][dipi_breadcrumbs _builder_version=”4.16″ _module_preset=”default” max_width=”800px” global_colors_info=”{}”][\/dipi_breadcrumbs][et_pb_divider color=”#EEEEEE” _builder_version=”4.16″ _module_preset=”default” max_width=”800px” min_height=”1px” height=”20px” custom_margin=”||3px|||” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.18.0″ _module_preset=”8738c908-7375-4c6c-99a7-9f91f8a3c099″ header_font_size=”56px” max_width=”800px” custom_margin=”|-49px|17px|||” global_colors_info=”{}”]<\/p>\n

TK 210 ELISA<\/h6>\n

Cell Proliferation Biomarker.<\/b><\/h1>\n
The AroCell TK 210 ELISA kit is a valuable biomarker for tumor cell turnover that aids in prognosis and monitoring therapy in subjects with hematological malignancies and different types of solid tumors such as breast, prostate, and ovary.\u00a0<\/h5>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.18.0″ _module_preset=”e9afc0e7-c9bf-4a12-be49-63ddba231101″ custom_padding=”30px||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

AroCell TK 210 ELISA<\/h3>\n

AroCell TK 210 ELISA is a quantitative immunoassay kit for the determination of human Thymidine Kinase 1 (TK1) protein concentration measured in a blood sample. The measurement of TK1 can be used as an aid in the management of cancer patients, in conjunction with other clinical and diagnostic procedures. TK1 levels at diagnosis can signal whether the tumor is local or spread and how aggressive the disease is. AroCell TK 210 ELISA also makes it possible to follow treatment outcomes and relapses in people with hematological and solid tumors. AroCell TK 210 ELISA provides valuable information that can be used for predicting and monitoring patients to help clinicians optimize treatment, monitoring, and follow-up.<\/p>\n

The ELISA format is simple and robust, requires no unique instrumentation to perform, and can easily be incorporated into standard laboratory processes. By utilizing monoclonal antibodies specific to the TK 210 epitope of TK1, AroCell TK 210 ELISA brings improved sensitivity and specificity to the assay of this key biomarker. The kit protocol includes a pre-treatment step of the samples using a proprietary sample dilution buffer that releases TK1 from its aggregates and makes it more readily accessible for accurate measurements. The method measures both active and inactive TK1 in blood.<\/p>\n

AroCell TK 210 ELISA was registered for CE marking 2015 and can be easily adapted to an automated analytical instrument.<\/p>\n

TK 210 ELISA is manufactured by AroCell AB.<\/strong><\/p>\n

[\/et_pb_text][et_pb_toggle title=”Thymidine Kinase 1″ _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Thymidine Kinase 1 (TK1) is an enzyme that is up-regulated in proliferating cells and peaks during of the S-phase of the cell cycle. The enzyme concentration is very low in resting cells. Thymidine Kinase 1 has become increasingly interesting in cancer research, drug development, and clinical oncology as it has been found that elevated levels of TK1 in blood is associated with the presence of malignancies. A malignant tumor has high cell division, and TK1 leaks out into the blood as a consequence of cell disruption spontaneously or triggered by therapy.<\/p>\n

Therefore, a sensitive routine test for measuring TK1 protein is of great value in patient monitoring, clinical research, and drug discovery and development. Thymidine Kinase 1 is a valuable biomarker in subjects with many forms of cancer, including leukemia, lymphoma, breast, prostate, lung, sarcoma, and colon cancer patients.\u00a0<\/p>\n

[\/et_pb_toggle][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/idldiagnostics.com\/wp-content\/uploads\/2022\/09\/arocell-laboratory-2.jpg” title_text=”arocell laboratory-2″ _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Find more information<\/h3>\n

The application of the AroCell TK 210 ELISA and the use of TK1 have been successfully used and described in several publications.<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/idldiagnostics.com\/wp-content\/uploads\/2022\/08\/AroCell-Breast-Cancer-Scientific-bibliography.pdf” url_new_window=”on” button_text=”Breast Cancer Bibliography” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_button][et_pb_button button_url=”https:\/\/idldiagnostics.com\/wp-content\/uploads\/2022\/08\/AroCell-Prostate-Cancer-Scientific-bibliography.pdf” url_new_window=”on” button_text=”Prostate Cancer Bibliography” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_button][et_pb_button button_url=”https:\/\/idldiagnostics.com\/wp-content\/uploads\/2022\/08\/TK-210-ELISA-Product-Sheet.pdf” url_new_window=”on” button_text=”Product Sheet” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_button][et_pb_button button_url=”http:\/\/eifu.arocell.com” url_new_window=”on” button_text=”Instructions for Use” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Clinical Evaluation<\/h3>\n

The application of the AroCell TK 210 ELISA and the use of TK1 have been successfully used and described in several publications.<\/p>\n

[\/et_pb_text][et_pb_accordion open_toggle_text_color=”#21242A” closed_toggle_background_color=”#EEEEEE” icon_font_size=”25px” _builder_version=”4.21.2″ _module_preset=”default” toggle_font=”Abel|300|||||||” body_ol_font_size=”15px” custom_margin=”||||false|false” custom_padding=”||||false|false” hover_enabled=”0″ border_radii=”on|3px|3px|3px|3px” border_width_bottom=”0px” global_colors_info=”{}” sticky_enabled=”0″][et_pb_accordion_item title=”*R\u00f6r ej*” open=”off” _builder_version=”4.18.0″ _module_preset=”default” custom_css_main_element=”display:none;” global_colors_info=”{}”]<\/p>\n

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.<\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”General” _builder_version=”4.21.2″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” open=”off” sticky_enabled=”0″]<\/p>\n

1.\u00a0Zhou,\u202fJ.\u202fet\u202fal.\u202f(2013).\u202fThe\u202fProliferation\u202fMarker\u202fThymidine\u202fKinase\u202f1\u202fin\u202fClinical\u202fUse.<\/a>\u202fReview. Molecular and Clinical Oncology 1:\u202f28.<\/p>\n

2.\u00a0Alegre,\u202fM.M.\u202fet\u202fal.\u202f(2012).\u202fThymidine\u202fKinase\u202f1\u202fUpregulation\u202fis\u202fan\u202fEarly\u202fEvent\u202fin\u202fBreast\u202fTumor Formation.<\/a>\u202fJournal\u202fof\u202fOncology. Volume 2012, Article ID 575647, \u202f5\u202fpages.<\/p>\n

3. Guan,\u202fH.\u202fet\u202fal.\u202f(2009).\u202fThymidine\u202fKinase\u202f1\u202fExpression in Atypical Ductal Hyperplasia Significantly Differs from Usual Ductal Hyperplasia and Ductal Carcinoma In-Situ: A Useful Tool in Tumor \u202fTherapy Management.<\/a> Mol Med Rep.\u202f2(6):\u202f923-9.<\/p>\n

4.\u00a0Alegre,\u202fM.M.\u202fet\u202fal.\u202f(2013).\u202fThymidine\u202fKinase\u202f1:\u202fA\u202fUniversal\u202fMarker\u202ffor\u202fCancer<\/a>. Cancer and Clinical Oncology. 2(1):\u202f2013.<\/p>\n

5. Bj\u00f6hle,\u202f J. et al. (2013). Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial.<\/a>\u202fBreast Cancer Res Treat. 139(3):\u202f751-8.<\/p>\n

6. Chen,\u202fF.\u202fet\u202fal.\u202f(2013). Serum thymidine kinase 1 levels predict cancer-free survival following neoadjuvant, surgical and adjuvant treatment of patients with locally advanced breast cancer.<\/a> Molecular and Clinical Oncology.\u202f 1:\u202f894-902.<\/p>\n

7. He,\u202fQ.\u202fet\u202fal.\u202f(2006).\u202fThymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer.<\/a>\u202f Anticancer Research 26: 4753-4760.<\/p>\n

8. Jagarlamudi,\u202fK.K.\u202fet\u202fal.\u202f(2015).\u202fBreast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker.<\/a> BMC Cancer 15:66.<\/p>\n

9. Kumar,\u202fJ.K.\u202fet\u202fal.\u202f(2016).\u202fA clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease<\/a>. Tumor Biology. 37: 11937.<\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”Prostate” _builder_version=”4.21.2″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” open=”off” sticky_enabled=”0″]<\/p>\n

10. Sung H, Ferlay J, Siegel RL, et al.\u202fGlobal Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.<\/a>\u202fCA: A Cancer Journal for Clinicians. 2021;71(3):209-249. doi:10.3322\/caac.21660.<\/p>\n

11. Jagarlamudi, K. K., Zupan, M., Kumer, K., Fabjan, T., Hlebi\u010d, G., Eriksson, S., et al. (2019). The Combination of AroCell TK 210 ELISA with Prostate Health Index or Prostate-specific Antigen Density Can Improve the Ability to Differentiate Prostate Cancer from Noncancerous Conditions.<\/a> Prostate 79 (8), 856\u2013863.<\/p>\n

12. Li, S., Zhou, J., Wang, Y., Zhang, K., Yang, J., Zhang, X., et al. (2018). Serum Thymidine Kinase 1 Is Associated with Gleason Score of Patients with Prostate Carcinoma.<\/a> Oncol. Lett. 16 (5), 6171\u20136180. Epub 2018\/10\/20PubMed PMID: 30333882; PubMed Central PMCID: PMCPMC6176382. doi:10.3892\/ol.2018. 9345<\/p>\n

13. Steineck, G.\u202fTK1 as prognostic\/predictive marker in metastatic prostate cancer.\u202fAroCell internal\u202freport (70-19CL21001-01- technical).<\/p>\n

 <\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”Breast” _builder_version=”4.21.2″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” open=”off” sticky_enabled=”0″]<\/p>\n

14. Jagarlamudi,\u202fK.K.\u202fand\u202fShaw\u202fM.\u202f(2018).\u202fThymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker.<\/a> Biomark. Med. 12(9):\u202f1035-1048.<\/p>\n

15.\u00a0Tribukait, B. Dynamics of Serum Thymidine Kinase 1 at the First Cycle of Neoadjuvant Chemotherapy Predicts Outcome of Disease in Estrogen-Receptor-Positive Breast Cancer.<\/a>\u202fCancers\u202f2021,\u202f13, 5442.<\/p>\n

16. Tribukait, B. Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume.<\/a> BMC Cancer\u202f2020,\u202f20, 440.<\/p>\n

17.\u00a0Steineck, G.\u202fTK1 based\u202fmalignant-\u202fcell\u202fdisruption metric based on Promix clinical trial.\u202fAroCell internal report\u202f2020\u202f(70-1RE20001).<\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”DLBCL” _builder_version=”4.21.2″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” open=”off” sticky_enabled=”0″]<\/p>\n

18. Jaffe ES, Harris NL, Stein H, et al., editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissue. Lyon: IARC Press; 2001.<\/p>\n

19.\u00a0A predictive model for aggressive non-Hodgkin\u2019s lymphoma.<\/a> The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N\u202fEngl\u202fJ Med\u202f1993; 329:987\u2013994.<\/p>\n

20.\u00a0Sehn\u202fLH, Berry B,\u202fChhanabhai\u202fM, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP<\/a>. Blood 2007;109;1857\u20131861.<\/p>\n

21.\u00a0Suzuki K,\u202fTerui\u202fY,\u202fYokoyama\u202fM, et al.\u202fPrognostic value of high thymidine kinase activity in patients with previously untreated diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone.<\/a> Leuk Lymphoma. 2013; 54:2412\u20132417.<\/p>\n

22. Erisksson\u202fS. Thymidine kinase 1 in diffuse large B-cell Lymphoma revisited in the Rituximabera. AroCell internal report\u202f(70-09CL22001-01).<\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”Ovarian” _builder_version=”4.21.2″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” open=”on” sticky_enabled=”0″]<\/p>\n

23.\u00a0Sung H, Ferlay J, Siegel RL, et al.\u202fGlobal Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries<\/a>.\u202fCA: A Cancer Journal for Clinicians. 2021;71(3):209-249. doi:10.3322\/caac.21660.<\/p>\n

24.\u00a0Zhu, C.,Zhang,\u202fN.,\u202fZhong,\u202fA.,\u202fXiao,\u202fK.,\u202fLu,\u202fR.,\u202fGuo,\u202fL., et al. (2022).\u202fA combined\u202fstrategy of TK1, HE4 and CA 125 shows better diagnostic\u202fperformance than risk of ovarian malignancy\u202falgorithm (ROMA)in ovarian carcinoma.<\/a>\u202fClin\u202fChim\u202fActa\u202f524,\u202f43\u201350.<\/p>\n

25.\u00a0Kiran J.\u202fTK1\u202fconcentrations\u202fas prognostic\u202fmarker in patients with ovarian cancer.\u202fAroCell internal\u202freport (70-20CL22002-01- technical).<\/p>\n

[\/et_pb_accordion_item][\/et_pb_accordion][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.17.4″ _module_preset=”default” global_module=”3323″ saved_tabs=”all” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_menu menu_id=”51″ disabled_on=”on|on|off” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_menu][et_pb_sidebar area=”et_pb_widget_area_10″ disabled_on=”off|off|on” _builder_version=”4.18.0″ _module_preset=”2efbbc8f-7ecb-4fe3-9956-d83a8a0e7a74″ background_color=”#F8F8F8″ locked=”off” global_colors_info=”{}”][\/et_pb_sidebar][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ custom_padding_last_edited=”on|tablet” _builder_version=”4.16″ _module_preset=”default” custom_padding_tablet=”||0px||false|false” custom_padding_phone=”” global_module=”2365″ saved_tabs=”all” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Oncology<\/h6>\n

Diagnostics for oncology<\/h3>\n

Cancer is one of the leading causes of death worldwide, despite advancing knowledge. To improve cancer patient management, there is a clear need for efficient diagnostics tools to capture this critical clinical data.<\/span><\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/idldiagnostics.com\/products\/oncology\/” button_text=”Read more about Oncology” _builder_version=”4.18.0″ _module_preset=”5e8c1032-9074-49bb-92a6-99c20ecc3d02″ global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/idldiagnostics.com\/wp-content\/uploads\/2022\/10\/girl-sunset.jpeg” title_text=”Happy smiling running beagle dog portrait with tongue out and owner female jogging by the mounting meadow grass path. Walking in nature with pets, happy healthy active people lifestyle concept image.” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ custom_padding_last_edited=”on|tablet” _builder_version=”4.16″ _module_preset=”default” custom_padding_tablet=”||0px||false|false” custom_padding_phone=”” global_module=”2428″ saved_tabs=”all” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Bacteriology<\/h6>\n

An effective typhoid test<\/h3>\n

Typhoid fever is water and food-borne infectious disease caused by the bacterium, Salmonella<\/em> enterica. IDL Biotechs product TUBEX\u00ae TF, is a rapid and sensitive in vitro diagnostic test for the detection of acute typhoid fever.<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/idldiagnostics.com\/products\/bacteriology\/” button_text=”Read more about bacteriology” _builder_version=”4.18.0″ _module_preset=”5e8c1032-9074-49bb-92a6-99c20ecc3d02″ global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/idldiagnostics.com\/wp-content\/uploads\/2022\/10\/girl-water.jpeg” title_text=”Water is Life for African Children, Little Gorgeous Black Girl Drinking from Tap” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ custom_padding_last_edited=”on|tablet” _builder_version=”4.16″ _module_preset=”default” custom_padding_tablet=”||0px||false|false” custom_padding_phone=”” global_module=”2175″ saved_tabs=”all” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Investors<\/h6>\n

We are listed on NASDAQ First North Growth Market.<\/h3>\n

We want to be the obvious choice within our segment in the markets where we are established. The market for our products is large and we are a smaller player with significant growth potential so far. AroCell is unique for a company of this size.<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/idldiagnostics.com\/investors\/” button_text=”Read more about investing” _builder_version=”4.18.0″ _module_preset=”5e8c1032-9074-49bb-92a6-99c20ecc3d02″ global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/idldiagnostics.com\/wp-content\/uploads\/2022\/10\/MG_3045.jpg” title_text=”_MG_3045″ _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t\t
\n